Endocrinol Metab.  2024 Oct;39(5):693-695. 10.3803/EnM.2024.2096.

Insulin-Like Growth Factor 1 as a Pillar in Acromegaly: From Diagnosis to Long-Term Management

• Kim MK

• KMID: 2560276
• DOI: http://doi.org/10.3803/EnM.2024.2096

Figure

• 

  Fig. 1. Overview of the diagnosis and management of patients with acromegaly and evolution of biochemical criteria for the diagnosis of acromegaly and assessment of treatment efficacy. MRI, magnetic resonance imaging; GH, growth hormone; IGF-1, insulin-like growth factor 1; ULN, upper limit of normal; OGTT, 75-g oral glucose tolerance test.

Reference

1. Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022; 10:804–26.

2. Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G, et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol. 2021; 185:251–63.

3. Korean Endocrine Society. Endocrine rare diseases fact sheet 2022. Seoul: Korean Endocrine Society;2002.

4. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006; 355:2558–73.

5. Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024; 27:7–22.

6. Peixe C, Sanchez-Garcia M, Grossman AB, Korbonits M, Marques P. Biochemical discrepancies in the evaluation of the somatotroph axis: elevated GH or IGF-1 levels do not always diagnose acromegaly. Growth Horm IGF Res. 2022; 64:101467.

7. Jung IH, Choi S, Ku CR, Lee SG, Lee EJ, Kim SH, et al. Revisiting the role of insulin-like growth factor-1 measurement after surgical treatment of acromegaly. J Clin Endocrinol Metab. 2021; 106:e2589–99.

8. Chin SO, Ku CR, Kim BJ, Kim SW, Park KH, Song KH, et al. Medical treatment with somatostatin analogues in acromegaly: position statement. Endocrinol Metab (Seoul). 2019; 34:53–62.